AGEN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

53.10M

+97.85%

-0.353

-82.68%

65.80M

+173.41%

0.620

-160.19%

28.20M

+9.73%

-0.490

-51%

Estimates Revision

The market is revising Downward the revenue expectations for Agenus Inc. (AGEN) for FY2025, with the revenue forecasts being adjusted by -28.88% over the past three months. During the same period, the stock price has changed by -1.51%.

Revenue Estimates for FY2025

Revise Downward

-28.88%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+18.83%

In Past 3 Month

Stock Price

Go Down

-1.51%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast AGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGEN is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

23.00

Averages

23.00

High

23.00

Current: 0.000

Low

23.00

Averages

23.00

High

23.00

H.C. Wainwright

Neutral -> Buy

upgrade

$25

2025-06-04

Reason

H.C. Wainwright

Price Target

$25

2025-06-04

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded Agenus to Buy from Neutral with a $25 price target after the company entered into a strategic collaboration with Indian multinational pharmaceutical company Zydus Lifesciences. The definitive partnership is valued at up to $141M and is aimed at accelerating the clinical development of botensilimab and balstilimab while also securing scaled manufacturing both domestically and outside the U.S., the analyst tells investors in a research note. Th firm says that given Agenus' commitment to reducing its cash burn and the capital provided from this partnership, it now believes the company has sufficient funding to advance botensilimab and balstilimab through a Phase 3 trial initiating in the second half of 2025.

Baird

Neutral

maintain

$4 -> $6

2025-06-04

Reason

Baird

Price Target

$4 -> $6

2025-06-04

maintain

Neutral

Reason

Baird raised the firm's price target on Agenus to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.

Baird

Neutral

maintain

$3 -> $4

2025-05-13

Reason

Baird

Price Target

$3 -> $4

2025-05-13

maintain

Neutral

Reason

Baird raised the firm's price target on Agenus to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where the cmpoany is evaluating multiple proposals which are expected to bring in capital.

HC Wainwright & Co.

Emily Bodnar

Hold

Reiterates

n/a

2025-03-18

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

n/a

2025-03-18

Reiterates

Hold

Reason

HC Wainwright & Co.

Emily Bodnar

Hold

Reiterates

n/a

2025-03-12

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

n/a

2025-03-12

Reiterates

Hold

Reason

Baird

Colleen Kusy

Hold

Maintains

$6 → $3

2025-03-12

Reason

Baird

Colleen Kusy

Price Target

$6 → $3

2025-03-12

Maintains

Hold

Reason

Baird lowered the firm's price target on Agenus to $3 from $6 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results and looks to focus on operational efficiency.

Valuation Metrics

The current forward P/E ratio for Agenus Inc (AGEN.O) is 24.53, compared to its 5-year average forward P/E of -4.28. For a more detailed relative valuation and DCF analysis to assess Agenus Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.28

Current PE

24.53

Overvalued PE

19.81

Undervalued PE

-28.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.67

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.70

Undervalued EV/EBITDA

-2.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.91

Current PS

0.54

Overvalued PS

10.20

Undervalued PS

-0.38

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AGEN News & Events

Events Timeline

No data

News

2.0

01-05NASDAQ.COM

Agenus (AGEN) Q1 2025 Earnings Call Transcript

9.0

2025-12-12Newsfilter

Oncolytics Biotech Secures FDA Approval for First Pancreatic Cancer Immunotherapy

5.0

2025-11-18Newsfilter

Agenus Names Dr. José Iglesias as Chief Medical Affairs Officer to Lead Global Medical Affairs and Early-Access Initiatives, Including France's AAC

People Also Watch

Frequently Asked Questions

What is Agenus Inc (AGEN) stock price today?

The current price of AGEN is 3.91 USD — it has increased 4.27 % in the last trading day.

What is Agenus Inc (AGEN)'s business?

Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

What is the price predicton of AGEN Stock?

What is Agenus Inc (AGEN)'s revenue for the last quarter?

Agenus Inc revenue for the last quarter amounts to 30.24M USD, increased 20.40 % YoY.

What is Agenus Inc (AGEN)'s earnings per share (EPS) for the last quarter?

Agenus Inc. EPS for the last quarter amounts to 1.94 USD, decreased -162.99 % YoY.

What changes have occurred in the market's expectations for Agenus Inc (AGEN)'s fundamentals?

How many employees does Agenus Inc (AGEN). have?

Agenus Inc (AGEN) has 316 emplpoyees as of January 10 2026.

What is Agenus Inc (AGEN) market cap?

Today AGEN has the market capitalization of 127.53M USD.